Implications of the upcoming changes to French ATU (Autorisation Temporaire d’Utilisation) programme CONTEXT: From July of 2021manufacturers will be required to make all early access authorisation requests to the HAS Continue Reading
CONTEXT: Presentation of a retrospective study in migraine epidemiology in Southern Israel at the 7th Congress of the European Academy of Neurology (EAN). Findings showed extreme variability in the prevalence Continue Reading
CONTEXT: A teaser article for the DIA 2021 where discussions are expected around decentralised trials and accelerated approval pathways. The DIA has always a great place for the industry to Continue Reading
CONTEXT: New data being presented at the European Hematology Association (EHA) 2021 Virtual Congress on the treatment of sickle cell disease with Oxbryta (voxelotor). Two real-world evidence studies support the Continue Reading
CONTEXT: Continuing this years theme of presenting RWR posters alongside traditional RCTs, Teva showed off their AJOVY (fremanezumab-vfrm) treatment for migraine at the American Headache Society annual meeting. Also included Continue Reading
CONTEXT: A philanthropy-fuelled database created at the University of Calgary is proving its value and attracting international attention, including for some highly encouraging new research for treating lung cancer (NSCLC) | Cananda only data Continue Reading
CONTEXT: Commercial announcement of CVS Health joining the push for decentralised clinical trials with the formation of a new business unit. This pharmacy chain is just the latest in a Continue Reading
CONTEXT: Report of the summit held in April 2021 by the Centre for Medical Cannabis on the future of medical cannabis in Britain. The report includes reference to a Continue Reading
CONTEXT: An interview article with a UK based company looking to bring “natural” psilocybin medicines to market through RWE studies and dodge the usual RCT regulatory routes. One to watch Continue Reading
CONTEXT: Commercial announcement of new applications of existing software from Clarify Health, delivering RWE software products for the pharma and biotech industries. IMPACT: Low READ TIME: 2 mins Quality Level Continue Reading
